Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR9.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR26.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR24.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR22.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR18.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR25.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR15.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR27.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR13.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR20.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR19.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR21.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR23.htm
EX-32 - PROGENICS EXHIBIT 32 09/30/2012 - PROGENICS PHARMACEUTICALS INCex3209302012.htm
EX-12.1 - PROGENICS EXHIBIT 12.1 09/30/2012 - PROGENICS PHARMACEUTICALS INCex12_109302012.htm
EX-31.1 - PROGENICS EXHIBIT 31.1 09/30/2012 - PROGENICS PHARMACEUTICALS INCex31_109302012.htm
XML - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCR17.htm
EX-31.2 - PROGENICS EXHIBIT 31.2 09/30/2012 - PROGENICS PHARMACEUTICALS INCex31_209302012.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

                                                                        
                                      

FORM 10-Q
 
(Mark One)
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2012
 
Or
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ___________ to ___________


Commission File No. 000-23143




PROGENICS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware
13-3379479
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification Number)



777 Old Saw Mill River Road
Tarrytown, NY 10591
(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (914) 789-2800
 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer  ¨
Accelerated filer   x
Non-accelerated filer    ¨  (Do not check if a smaller reporting company)
Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   No x
 
As of November 5, 2012, 33,915,472 shares of the registrant's common stock, par value $.0013 per share, were outstanding.
 




PROGENICS PHARMACEUTICALS, INC.
 
INDEX
 
 
 
Page No.
Part I
FINANCIAL INFORMATION
 
Item 1.
 
 
3
 
4
 
5
 
6
 
7
 
8
Item 2.
15
Item 3.
25
Item 4.
25
 
 
 
PART II
 
Item 1A.
26
Item 6.
27
 
28

 

 

 
2


 


PART I — FINANCIAL INFORMATION
 
Item 1. Financial Statements
 
PROGENICS PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
 
(amounts in thousands, except for par value and share amounts)

 
 
September 30, 2012
   
December 31, 2011
 
 
 
(Unaudited)
   
 
Assets
 
   
 
Current assets:
 
   
 
Cash and cash equivalents
 
$
41,096
   
$
70,105
 
Accounts receivable
   
1,129
     
1,516
 
Other current assets
   
1,186
     
919
 
Total current assets
   
43,411
     
72,540
 
Auction rate securities
   
3,240
     
3,332
 
Fixed assets, at cost, net of accumulated depreciation and amortization
   
3,650
     
4,038
 
Other assets
   
200
     
200
 
Total assets
 
$
50,501
   
$
80,110
 
 
               
Liabilities and Stockholders' Equity
               
Current liabilities:
               
Accounts payable and accrued expenses
 
$
6,486
   
$
6,331
 
Deferred revenue - current
   
204
     
204
 
Other current liabilities
   
115
     
115
 
Total current liabilities
   
6,805
     
6,650
 
Deferred revenue - long term
   
9
     
162
 
Other liabilities
   
1,039
     
1,497
 
Total liabilities
   
7,853
     
8,309
 
Commitments and contingencies (Note 8)
               
Stockholders' equity:
               
Preferred stock, $.001 par value; 20,000,000 shares authorized; issued and outstanding – none
   
-
     
-
 
Common stock, $.0013 par value; 80,000,000 shares authorized; issued – 34,076,951 in 2012 and 34,046,409 in 2011
   
44
     
44
 
Additional paid-in capital
   
469,386
     
463,440
 
Accumulated deficit
   
(423,781
)
   
(388,674
)
Accumulated other comprehensive loss
   
(260
)
   
(268
)
Treasury stock, at cost (200,000 shares in 2012 and 2011)
   
(2,741
)
   
(2,741
)
Total stockholders' equity
   
42,648
     
71,801
 
Total liabilities and stockholders' equity
 
$
50,501
   
$
80,110
 



The accompanying notes are an integral part of these unaudited consolidated financial statements.
3


PROGENICS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
 
(amounts in thousands, except net (loss) income per share)
(Unaudited)

 
 
For the Three Months Ended
   
For the Nine Months Ended
 
 
 
September 30,
   
September 30,
 
 
 
2012
   
2011
   
2012
   
2011
 
Revenues:
 
   
   
   
 
Royalty income
 
$
728
   
$
1,240
   
$
4,181
   
$
1,767
 
Collaboration revenue
   
136
     
2,855
     
521
     
76,398
 
Research grants
   
243
     
1,681
     
417
     
4,346
 
Other revenues
   
10
     
28
     
44
     
88
 
Total revenues
   
1,117
     
5,804
     
5,163
     
82,599
 
 
                               
Expenses:
                               
Research and development
   
7,551
     
12,406
     
26,417
     
44,887
 
License fees – research and development
   
510
     
114
     
660
     
566
 
Royalty expense
   
73
     
147
     
420
     
274
 
General and administrative
   
4,007
     
4,064
     
11,753
     
14,213
 
Depreciation and amortization
   
291
     
520
     
1,063
     
1,581
 
Total expenses
   
12,432
     
17,251
     
40,313
     
61,521
 
 
                               
Operating (loss) income
   
(11,315
)
   
(11,447
)
   
(35,150
)
   
21,078
 
 
                               
Other income:
                               
Interest income
   
14
     
15
     
43
     
49
 
Total other income
   
14
     
15
     
43
     
49
 
 
                               
Net (loss) income
 
$
(11,301
)
 
$
(11,432
)
 
$
(35,107
)
 
$
21,127
 
 
                               
Net (loss) income per share - basic
 
$
(0.33
)
 
$
(0.34
)
 
$
(1.04
)
 
$
0.63
 
Weighted-average shares - basic
   
33,848
     
33,710
     
33,803
     
33,501
 
 
                               
Net (loss) income per share - diluted
 
$
(0.33
)
 
$
(0.34
)
 
$
(1.04
)
 
$
0.63
 
Weighted-average shares - diluted
   
33,848
     
33,710
     
33,803
     
33,664
 




The accompanying notes are an integral part of these unaudited consolidated financial statements.
4



PROGENICS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(amounts in thousands)
(Unaudited)


 
 
For the Three Months Ended
   
For the Nine Months Ended
 
 
 
September 30,
   
September 30,
 
 
 
2012
   
2011
   
2012
   
2011
 
 
 
   
   
   
 
Net (loss) income
 
$
(11,301
)
 
$
(11,432
)
 
$
(35,107
)
 
$
21,127
 
Other comprehensive income:
                               
Net change in unrealized loss on auction rate securities
   
-
     
8
     
8
     
16
 
Total other comprehensive income
   
-
     
8
     
8
     
16
 
  Comprehensive (loss) income
 
$
(11,301
)
 
$
(11,424
)
 
$
(35,099
)
 
$
21,143
 


The accompanying notes are an integral part of these unaudited consolidated financial statements.

5



PROGENICS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011
 
(amounts in thousands)
(Unaudited)
 
 
 
Common Stock
         
   
Accumulated Other
   
Treasury Stock
   
 
 
 
Shares
   
Amount
   
Additional
Paid-In Capital
   
Accumulated Deficit
   
Comprehensive Income (Loss)
   
Shares
   
Amount
   
Total
 
Balance at December 31, 2011
   
34,046
   
$
44
   
$
463,440
   
$
(388,674
)
 
$
(268
)
   
(200
)
 
$
(2,741
)
 
$
71,801
 
Net loss
   
-
     
-
     
-
     
(35,107
)
   
-
     
-
     
-
     
(35,107
)
Other comprehensive income
   
-
     
-
     
-
     
-
     
8
     
-
     
-
     
8
 
   Compensation expenses for share-based   payment arrangements
   
-
     
-
     
5,750
     
-
     
-
     
-
     
-
     
5,750
 
Forfeitures of restricted stock
   
(6
)
   
-
     
-
     
-
     
-
     
-
     
-
     
-
 
Exercise of stock options
   
37
     
-
     
196
     
-
     
-
     
-
     
-
     
196
 
Balance at September 30, 2012
   
34,077
   
$
44
   
$
469,386
   
$
(423,781
)
 
$
(260
)
   
(200
)
 
$
(2,741
)
 
$
42,648
 

 
 
Common Stock
         
   
Accumulated Other
   
Treasury Stock
   
 
 
 
Shares
   
Amount
   
Additional
Paid-In Capital
   
Accumulated Deficit
   
Comprehensive Income (Loss)
   
Shares
   
Amount
   
Total
 
Balance at December 31, 2010
   
33,326
   
$
43
   
$
453,353
   
$
(399,055
)
 
$
(292
)
   
(200
)
 
$
(2,741
)
 
$
51,308
 
Net income
   
-
     
-
     
-
     
21,127
     
-
     
-
     
-
     
21,127
 
Other comprehensive income
   
-
     
-
     
-
     
-
     
16
     
-
     
-
     
16
 
   Compensation expenses for share-based payment arrangements
   
-
     
-
     
4,695
     
-
     
-
     
-
     
-
     
4,695
 
  Issuance of restricted stock, net of forfeitures
   
(34
)
   
-
     
-
     
-
     
-
     
-
     
-
     
-
 
  Sale of common stock under employee stock purchase plans and exercise of stock options
   
665
     
1
     
3,233
     
-
     
-
     
-
     
-
     
3,234
 
Balance at September 30, 2011
   
33,957
   
$
44
   
$
461,281
   
$
(377,928
)
 
$
(276
)
   
(200
)
 
$
(2,741
)
 
$
80,380
 

The accompanying notes are an integral part of these unaudited consolidated financial statements.
6




PROGENICS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
(amounts in thousands)
(Unaudited)

 
 
For the Nine Months Ended
 
 
 
September 30,
 
 
 
2012
   
2011
 
Cash flows from operating activities:
 
   
 
Net (loss) income
 
$
(35,107
)
 
$
21,127
 
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
               
Depreciation and amortization
   
1,063
     
1,581
 
Gains on sales of fixed assets
   
(307
)
   
-
 
Expenses for share-based compensation awards
   
5,750
     
4,695
 
Changes in assets and liabilities:
               
Decrease (increase) in accounts receivable
   
387
     
(229
)
(Increase) decrease in other current assets
   
(244
)
   
986
 
Decrease in other assets
   
-
     
1,050
 
Increase (decrease) in accounts payable and accrued expenses
   
155
     
(2,802
)
Increase in deferred revenue - current
   
-
     
204
 
(Decrease) increase in deferred revenue - long term
   
(153
)
   
213
 
Decrease in other liabilities
   
(458
)
   
(37
)
Net cash (used in) provided by operating activities
   
(28,914
)
   
26,788
 
Cash flows from investing activities:
               
Capital expenditures
   
(759
)
   
(142
)
Proceeds from sales of fixed assets
   
368
     
-
 
Proceeds from redemption of auction rate securities
   
100
     
200
 
Net cash (used in) provided by investing activities
   
(291
)
   
58
 
Cash flows from financing activities:
               
Proceeds from the exercise of stock options and sale of common stock under employee stock purchase plans
   
196
     
3,234
 
Net cash provided by financing activities
   
196
     
3,234
 
Net (decrease) increase in cash and cash equivalents
   
(29,009
)
   
30,080
 
Cash and cash equivalents at beginning of period
   
70,105
     
47,918
 
Cash and cash equivalents at end of period
 
$
41,096
   
$
77,998
 


The accompanying notes are an integral part of these unaudited consolidated financial statements.
7

PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (unaudited)
(amounts in thousands, except per share amounts or as otherwise noted)

1.  Interim Financial Statements

Progenics Pharmaceuticals, Inc. ("Progenics," "we" or "us") is dedicated to the development of innovative medicines to treat disease. In 2011, we licensed our first commercial product, Relistor® (methylnaltrexone bromide) subcutaneous injection, to Salix Pharmaceuticals, Inc., a leading gastrointestinal disease specialty company. Relistor is marketed directly by Salix through its specialty sales force in the United States and outside the U.S. by Salix's sublicensees and distributors except in Japan, where we have previously licensed to Ono Pharmaceutical Co., Ltd. the subcutaneous formulation of the drug.

Relistor is approved in the U.S., the European Union and elsewhere for treatment of opioid-induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient. Under our License Agreement, Salix is responsible for further developing and commercializing subcutaneous Relistor, including completing clinical development necessary to support regulatory marketing approvals for potential new indications and formulations of the drug. As part of those efforts, we and Salix have sought to expand the availability of subcutaneous Relistor to patients with chronic, non-cancer pain, and to develop an oral formulation of methylnaltrexone for use by such patients.
 
As previously announced, on July 27 the FDA issued a Complete Response Letter (CRL) requesting additional clinical data for the supplemental New Drug Application (sNDA) for Relistor injection for subcutaneous use for the treatment of OIC in adult patients with chronic, non-cancer pain. On October 5, an End-of-Review meeting was held with the FDA's Division of Gastroenterology and Inborn Errors Products to better understand the contents of the letter. The Division has expressed a concern that there may be a risk associated with the chronic use of mu-opioid antagonists in patients who are taking opioids for chronic pain. In order to understand this potential risk, the Division has communicated that a very large, well-controlled, chronic administration trial will have to be conducted to assess the safety of any mu-opioid antagonist prior to market approval for the treatment of patients with OIC who are taking opioids for chronic, non-cancer pain. Salix has held discussions with the Division and has expressed the view that the post-marketing, clinical and preclinical data currently available for Relistor adequately demonstrate an appropriate and expected safety profile sufficient to permit the approval of the current Relistor sNDA.

Salix and Progenics plan to continue to work with the FDA to generate a reasonable path forward for the further development and regulatory review of Relistor that can be agreed upon by the parties. While it is not possible to determine definitively the duration of discussions with the FDA regarding this matter, at this time Salix and Progenics anticipate a path forward could be reached with the FDA during 2013.
 
Progenics also has proprietary research and development programs for drug candidates focused on oncology. Our principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate (ADC) directed against prostate specific membrane antigen (PSMA), a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. PSMA ADC is in phase 2 clinical study and we are considering as appropriate strategic collaborations with biopharmaceutical companies for this compound. We are also conducting preclinical development work on novel phosphoinositide 3-kinase (PI3K) inhibitors to block signaling pathways critical in the growth of aggressive cancers, and are seeking to in-license or acquire other complementary opportunities in the oncology field and supportive, diagnostic and/or other areas.

As we have expanded our focus on oncology, we have terminated certain research efforts not within the Company's oncology focus, and are divesting or out-licensing others. In the third quarter we signed a non-binding term sheet, and are now in contract negotiations for disposition of our C. difficile program, and in October completed the divestment of the PRO 140 program, for which we received $3.5 million cash, together with rights to receive an additional $1.5 million upon commencement of a U.S. or ex-U.S. equivalent phase 3 trial of PRO 140, an additional $5.0 million upon U.S. or E.U. marketing approval of the drug, and a 5% royalty on net sales of approved product(s). Progenics also in the third quarter completed a companywide restructuring, including a workforce reduction and termination of several early stage research projects. Our clinical development and manufacturing capabilities were unaffected by this restructuring.

Progenics commenced principal operations in 1988, became publicly traded in 1997 and throughout has been engaged primarily in research and development efforts, establishing corporate collaborations and related activities. All of our operations are conducted at our facilities in Tarrytown, New York.
 

8

PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – continued (unaudited)
(amounts in thousands, except per share amounts or as otherwise noted)
 
Relistor (methylnaltrexone bromide) subcutaneous injection is a first-in-class therapy for OIC which we developed over the course of the last decade and since 2008 has been approved for sale in the U.S. and over 50 other countries worldwide, including countries in the E.U., Canada and Australia. Under our Agreement with Salix, we are eligible to receive (i) a development milestone of up to $40.0 million upon U.S. marketing approval for subcutaneous Relistor in non-cancer pain patients (the proposed indication addressed in the CRL mentioned above), (ii) a development milestone of up to $50.0 million upon U.S. marketing approval of an oral formulation of Relistor, (iii) up to $200.0 million of commercialization milestone payments upon achievement of specified U.S. sales targets, (iv) royalties ranging from 15 to 19 percent of net sales by Salix and its affiliates, and (v) 60% of any upfront, milestone, reimbursement or other revenue (net of costs of goods sold, as defined, and territory-specific research and development expense reimbursement) Salix receives from sublicensees outside the U.S. (for which we have received $0.2 million to date). In the event that either marketing approval is subject to a Black Box Warning or Risk Evaluation and Mitigation Strategy (REMS), payment of a substantial portion of the development milestone amount would be deferred, and subject, to achievement of the first commercialization milestone (payable upon annual U.S. sales first exceeding $100.0 million).

Funding and Financial Matters. At September 30, 2012, we held $41.1 million in cash and cash equivalents, a $6.7 million decrease from the second quarter-end, and a $29.0 million decrease from year-end 2011. We expect that this amount will be sufficient to fund operations as currently anticipated beyond one year. We currently use cash on hand and royalty payments from Relistor to fund our ongoing operations. We expect to continue to use cash on hand and future Relistor royalties and other revenues, including any future development and/or commercialization milestones, as well as payments we may receive for licenses or other transactions involving other proprietary assets and programs, to fund our operations in the future. If we do not realize sufficient royalty or other revenue from Relistor, or are unable to enter into favorable collaboration, license, asset sale, capital raising or other financing transactions, we will have to reduce, delay or eliminate spending on certain programs, and/or reduce headcount and other overhead expenses.

In April 2008, our Board of Directors approved a share repurchase program to acquire up to $15.0 million of our outstanding common shares, under which we have $12.3 million remaining available. Purchases may be discontinued at any time. We did not repurchase any common shares during the three or nine months ended September 30, 2012.

Our interim Consolidated Financial Statements included in this report have been prepared in accordance with applicable presentation requirements, and accordingly do not include all information and disclosures necessary for a presentation of our financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the U.S. ("GAAP"). In the opinion of management, these financial statements reflect all adjustments, consisting primarily of normal recurring accruals necessary for a fair statement of results for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. Our interim financial statements should be read in conjunction with the financial statements and notes thereto contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011. The year-end consolidated balance sheet data in these financial statements were derived from audited financial statements, but do not include all disclosures required by GAAP.

2.  Revenue Recognition

We recognize revenue from all sources based on the provisions of the SEC's Staff Accounting Bulletin (SAB) No. 104 (SAB 104) and ASC 605 Revenue Recognition. Under ASC 605, the delivered items are separate units of accounting, provided (i) the delivered items have value to a collaborator on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered items is considered probable and substantially in our control. In April 2010, the FASB issued a separate update to ASC 605 which provides guidance on the criteria that should be met when determining whether the milestone method of revenue recognition is appropriate. This method is effective on a prospective basis for milestones achieved after January 1, 2011.

There have been no changes to our revenue recognition accounting policies as of and for the nine months ended September 30, 2012 which policies are disclosed in Note 2 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2011.

License Agreement with Salix – February 2011

Under our License Agreement, Salix is responsible for further developing and commercializing Relistor worldwide other than Japan, including completing clinical development necessary to support regulatory marketing approvals for potential new indications and formulations. We have granted Salix an exclusive license of relevant know-how, patent rights and technology, assigned relevant third-party contracts and we are responsible for serving on joint committees provided for in the License Agreement. We expect to perform joint committee services through 2013. We recognized $0.2 million and $59.6 million during the nine months ended September 30, 2012 and 2011, respectively, and $59.6 million for the year ended December 31, 2011, all from the $60.0 million upfront payment. At September 30, 2012, the $0.2 million remaining deferred revenue, which pertains to joint committee services, will be recognized in collaboration revenue as such activities are performed in the future.

9

PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – continued (unaudited)
(amounts in thousands, except per share amounts or as otherwise noted)

3.  Net (Loss) Income Per Share

Our basic net (loss) income per share amounts have been computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period. As of September 30, 2012 and 2011, the 28 and 101 shares, respectively, of unvested restricted stock outstanding have non-forfeitable rights to dividends. The allocation of net loss and net income, in the respective periods, to these participating securities pursuant to the two-class method is not material to both basic and diluted earnings per share. For the three and nine months ended September 30, 2012 and for the three months ended September 30, 2011, we reported net losses and, therefore, potential common shares were not included in the computation of diluted net loss per share since such inclusion would have been anti-dilutive. For the nine months ended September 30, 2011, we reported net income, and the computation of diluted earnings per share is based upon the weighted-average number of common shares and dilutive effect, determined using the treasury stock method, of potential common shares outstanding. The calculations of net (loss) income per share, basic and diluted, are as follows:

 
 
Net (Loss) Income
(Numerator)
   
Weighted Average
Common Shares
(Denominator)
   
Per Share
Amount
 
Three months ended September 30, 2012
 
   
   
 
Basic and diluted
 
$
(11,301
)
   
33,848
   
$
(0.33
)
Nine months ended September 30, 2012
                       
Basic and diluted
 
$
(35,107
)
   
33,803
   
$
(1.04
)
Three months ended September 30, 2011
                       
Basic and diluted
 
$
(11,432
)
   
33,710
   
$
(0.34
)
Nine months ended September 30, 2011
                       
Basic
 
$
21,127
     
33,501
   
$
0.63
 
Dilutive effect of stock options
   
-
     
142
         
Dilutive effect of restricted stock
   
-
     
21
         
Diluted
 
21,127
     
33,664
   
$
0.63
 

For the three and nine months ended September 30, 2012 and 2011, anti-dilutive common shares excluded from diluted per share amounts consist of the following:

 
Three Months Ended September 30,
 
 
2012
   
2011
 
 
Weighted
Average
Number
   
Weighted
Average
Exercise Price
   
Weighted
Average
Number
   
Weighted
Average
Exercise Price
Options
   
6,035
   
$
12.22
     
6,186
   
$
12.65
Restricted stock
   
33
             
9
       
Total
   
6,068
             
6,195
       

 
Nine Months Ended September 30,
 
2012
2011
 
Weighted
Average
Number
Weighted
Average
Exercise Price
Weighted
Average
Number
Weighted
Average
Exercise Price
Options
6,019
$
12.31
4,126
$
15.78
Restricted stock
 
68
 
-
Total
 
6,087
 
4,126

4.  Fair Value Measurements

Our auction rate securities are recorded at fair value in the accompanying Consolidated Balance Sheets in accordance with ASC 320 Investments – Debt and Equity Securities. The change in the fair value of these investments is recorded as a component of other comprehensive (loss) income (see Note 2. Summary of Significant Accounting Policies - Fair Value Measurements in the notes to consolidated financial statements included in our 2011 Annual Report on Form 10-K).

The following tables present our money market funds and auction rate securities measured at fair value on a recurring basis as of September 30, 2012 and December 31, 2011, classified by valuation hierarchy:
10

PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – continued (unaudited)
(amounts in thousands, except per share amounts or as otherwise noted)
 
 
Fair Value Measurements at September 30, 2012
Investment Type
Balance at
September 30, 2012
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant
Other Observable Inputs
(Level 2)
Significant Unobservable
Inputs
(Level 3)
Money market funds
$
36,211
$
36,211
$
-
$
-
Auction rate securities
 
3,240
 
-
 
-
 
3,240
Total
$
39,451
$
36,211
$
-
$
3,240

 
Fair Value Measurements at December 31, 2011
Investment Type
Balance at
December 31, 2011
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant
Other Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Money market funds
$
64,068
$
64,068
$
-
$
-
Auction rate securities
 
 3,332
 
-
 
-
 
3,332
Total
$
67,400
$
64,068
$
-
$
3,332

At September 30, 2012, we hold $3,240 in auction rate securities which are classified as Level 3. The fair value of these securities includes $2,300 of U.S. government subsidized securities collateralized by student loan obligations, with maturities greater than 10 years, and $940 of investment company perpetual preferred stock, without a stated maturity. We will not realize cash in respect of the principal amount of these securities until the issuer calls or restructures the security, the security reaches any scheduled maturity and is paid, or a buyer outside the auction process emerges. As of September 30, 2012, we have received all scheduled interest payments on these securities, which, in the event of auction failure, are reset according to contractual terms in the governing instruments.

The valuation of auction rate securities we hold is based on Level 3 unobservable inputs which consist of our internal analysis of (i) timing of expected future successful auctions or issuer calls of the securities, (ii) collateralization of underlying assets of the security and (iii) credit quality of the security. We use a discounted cash flow model to estimate the value of these auction rate securities and the unobservable inputs consist of a redemption period ranging from four to 17 years (weighted-average: 6.6 years) and discount rates ranging from 0.25% to 2.39% (weighted-average: 1.1%). Significant increases (decreases) in the redemption period or discount rates would result in a significantly lower (higher) fair value measurement. In re-evaluating the valuation of these securities as of September 30, 2012, the temporary impairment amount, the duration of which is greater than 12 months, decreased $8 from $268 at December 31, 2011, to $260, which is reflected as part of accumulated other comprehensive loss on our accompanying Consolidated Balance Sheets and based on such re-evaluation, we believe that we have the ability to hold these securities until recovery of fair value. Due to the uncertainty related to the liquidity in the auction rate security market and therefore when individual positions may be liquidated, we have classified these auction rate securities as long-term assets on our accompanying Consolidated Balance Sheets. We continue to monitor markets for our investments and consider the impact, if any, of market conditions on the fair market value of our investments. We do not believe the carrying values of our investments are other than temporarily impaired and therefore expect the positions will eventually be liquidated without significant loss.

For our financial instruments with significant Level 3 inputs (all of which are auction rate securities), the following table summarizes the activities for the three and nine months ended September 30, 2012 and 2011:
11

PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – continued (unaudited)
(amounts in thousands, except per share amounts or as otherwise noted)


 
 
Fair Value Measurements Using Significant
Unobservable Inputs
(Level 3)
For the Three Months Ended September 30,
 
Description
 
2012
   
2011
 
Balance at beginning of period
 
$
3,240
   
$
3,516
 
Transfers into Level 3
   
-
     
-
 
Transfers out of Level 3
   
-
     
-
 
Total gains (losses)
               
Included in net loss
   
-
     
-
 
Included in other comprehensive loss
   
-
     
8
 
Settlements at par
   
-
     
(100
)
Balance at end of period
 
$
3,240
   
$
3,424
 
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets held at the end of the reporting period
 
$
-
   
$
-
 

 
 
Fair Value Measurements Using Significant
Unobservable Inputs
(Level 3)
For the Nine Months Ended September 30,
 
Description
 
2012
   
2011
 
Balance at beginning of period
 
$
3,332
   
$
3,608
 
Transfers into Level 3
   
-
     
-
 
Transfers out of Level 3
   
-
     
-
 
Total gains (losses)
               
Included in net loss
   
-
     
-
 
Included in other comprehensive loss
   
8
     
16
 
Settlements at par
   
(100
)
   
(200
)
Balance at end of period
 
$
3,240
   
$
3,424
 
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets held at the end of the reporting period
 
$
-
   
$
-
 

5.  Accounts Receivable

 
 
September 30,
2012
 
December 31,
2011
Royalties
 
$
728
 
$
1,279
Collaborators
   
314
   
77
Research grants
   
87
   
100
Other
   
-
   
60
Total
 
$
1,129
 
$
1,516

The decrease in accounts receivable as of September 30, 2012 as compared to December 31, 2011, is primarily due to lower Relistor royalties from decreased net sales by Salix during the third quarter of 2012. Since December 31, 2011, we have collected all accounts receivable outstanding on that date.
12

PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – continued (unaudited)
(amounts in thousands, except per share amounts or as otherwise noted)


6.  Accounts Payable and Accrued Expenses

 
 
September 30,
2012
 
December 31,
2011
Accrued payroll and related costs
 
$
1,845
 
$
3,149
Accrued consulting and clinical trial costs
   
1,964
   
1,637
Restructuring costs
   
1,886
   
731
Legal and professional fees
   
593
   
371
Accounts payable
   
125
   
309
Other
   
73
   
134
Total
 
$
6,486
 
$
6,331

Accounts payable and accrued expenses increased as of September 30, 2012, compared to year end, primarily due to higher restructuring costs and legal and professional fees, partially offset by decrease due to the payment of 2011 accrued bonuses in the first quarter of 2012.
 
7.  Restructurings

We reduced headcount in the third and fourth quarters of 2011, resulting in a restructuring accrual of $1.3 million for severance and related benefits which were paid through August 2012. We incurred other exit and contract termination costs, including expenses related to a lease amendment and consolidation of employees within reduced facility space.

We completed an additional headcount reduction in the third quarter of 2012, resulting in a restructuring accrual of $1.9 million which is being paid through August 2013, and we intend to pay up to $1.2 million in shares of common stock through the Company's 2005 Stock Incentive Plan. At the closing market price of the Company's common stock on September 30, 2012, up to 412,000 shares may be issued in satisfaction of this obligation.

Activity in the restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets, and in research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below.

 
 
Severance and Related
Benefits
   
Other
Exit
Costs
   
Contract Termination
Costs
   
Total
Restructuring Accrual
 
Balance at December 31, 2011
 
$
571
   
$
6
   
$
154
   
$
731
 
Additions, net
   
-
     
122
     
3
     
125
 
Payments
   
(456
)
   
(123
)
   
(147
)
   
(726
)
Balance at March 31, 2012
   
115
     
5
     
10
     
130
 
Additions, net
   
-
     
62
     
-
     
62
 
Payments
   
(93
)
   
(67
)
   
(10
)
   
(170
)
Balance at June 30, 2012
   
22
     
-
     
-
     
22
 
Additions, net
   
1,886
     
-
     
-
     
1,886
 
Payments
   
(22
)
   
-
     
-
     
(22
)
Balance at September 30, 2012
 
$
1,886
   
$
-
   
$
-
   
$
1,886
 
 
13

 
PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – continued (unaudited)
(amounts in thousands, except per share amounts or as otherwise noted)
 
 
8.  Commitments and Contingencies

In the ordinary course of our business, we enter into agreements with third parties, such as business partners, clinical sites and suppliers, that include indemnification provisions which in our judgment are normal and customary for companies in our industry sector. We generally agree to indemnify, hold harmless and reimburse the indemnified parties for losses suffered or incurred by them with respect to our products or product candidates, use of such products or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is not limited. We have not incurred material costs to defend lawsuits or settle claims related to these provisions. As a result, the estimated fair value of liabilities relating to indemnification provisions is minimal. We have no liabilities recorded for these provisions as of September 30, 2012.

 
14


Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations

Note Regarding Forward-Looking Statements

This document and other public statements we make may contain statements that do not relate strictly to historical fact, any of which may be forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. When we use the words "anticipates," "plans," "expects" and similar expressions, we are identifying forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, do not gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development might reduce the commercial potential of our products; we, our collaborators or others might identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not originating from subsequent testing or other activities by us, governmental regulators, other entities or organizations or otherwise, and whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, declining sales or other adverse events.

We are also subject to risks and uncertainties associated with the actions of our corporate, academic and other collaborators and government regulatory agencies, including risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; the risk that we may not be able to enter into favorable collaboration or other relationships or that existing or future relationships may not proceed as planned; the risk that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity, or that our rights to in-licensed intellectual property may be terminated for our failure to satisfy performance milestones; the risk of difficulties in, and regulatory compliance relating to, manufacturing products; and the uncertainty of our future profitability.

Risks and uncertainties also include general economic conditions, including interest and currency exchange-rate fluctuations and the availability of capital; changes in generally accepted accounting principles; the impact of legislation and regulatory compliance; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; trade buying patterns; the competitive climate of our industry; and other factors set forth in this document and other reports filed with the U.S. Securities and Exchange Commission (SEC). In particular, we cannot assure you that Relistor® will be commercially successful or be approved in the future in other formulations, indications or jurisdictions, or that any of our other programs will result in a commercial product.

We do not have a policy of updating or revising forward-looking statements and we assume no obligation to update any statements as a result of new information or future events or developments. It should not be assumed that our silence over time means that actual events are bearing out as expressed or implied in forward-looking statements.

Overview

General. Progenics Pharmaceuticals is dedicated to the development of innovative medicines to treat disease. Our focus is on the treatment of cancer.

Our first commercial drug is Relistor, for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer. OIC is the constipation that often arises when patients take opioids for pain relief. Relistor is the only prescription medicine approved in the United States to treat this form of constipation. Relistor subcutaneous injection is now approved in the U.S., the European Union and over 50 other countries around the world. In the U.S. Relistor is marketed by our commercial partner Salix Pharmaceuticals, a leading specialty pharmaceutical company focusing on gastrointestinal diseases and outside the U.S. by Salix sublicensees and distributors. Our partner Ono Pharmaceutical is currently developing subcutaneous Relistor for Japan.

As part of our efforts to develop and commercialize Relistor and its active ingredient, methylnaltrexone, we and Salix have sought to expand the availability of subcutaneous Relistor to patients taking opioids for non-cancer pain, and who suffer from OIC as a result (a population which includes patients taking opioids for conditions such as back pain or joint pain), and to develop an oral formulation of methylnaltrexone for use by such patients.
15

 
As previously announced, on July 27 the FDA issued a Complete Response Letter (CRL) requesting additional clinical data for the supplemental New Drug Application (sNDA) for Relistor injection for subcutaneous use for the treatment of OIC in adult patients with chronic, non-cancer pain. On October 5, an End-of-Review meeting was held with the FDA's Division of Gastroenterology and Inborn Errors Products to better understand the contents of the letter. The Division has expressed a concern that there may be a risk associated with the chronic use of mu-opioid antagonists in patients who are taking opioids for chronic pain. In order to understand this potential risk, the Division has communicated that a very large, well-controlled, chronic administration trial will have to be conducted to assess the safety of any mu-opioid antagonist prior to market approval for the treatment of patients with OIC who are taking opioids for chronic, non-cancer pain. Salix has held discussions with the Division and has expressed the view that the post-marketing, clinical and preclinical data currently available for Relistor adequately demonstrate an appropriate and expected safety profile sufficient to permit the approval of the current Relistor sNDA.

Salix and Progenics plan to continue to work with the FDA to generate a reasonable path forward for the further development and regulatory review of Relistor that can be agreed upon by the parties. While it is not possible to determine definitively the duration of discussions with the FDA regarding this matter, at this time Salix and Progenics anticipate a path forward could be reached with the FDA during 2013.
 
Our lead oncology product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate (ADC) directed against prostate specific membrane antigen (PSMA), a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. PSMA ADC is in phase 2 clinical study, and we are considering as appropriate strategic collaborations with biopharmaceutical companies for PSMA ADC. As a part of our work in oncology, we are also conducting preclinical development of novel phosphoinositide 3-kinase (PI3K) inhibitors, which we believe may be effective in blocking signaling pathways critical in the growth of aggressive cancers, particularly RAS-mutated tumors, and are seeking opportunities to expand our oncology pipeline through in-licensing and acquisitions.

With our focus on the development of medicines to treat cancer, we have discontinued development work on programs outside of this focus and are divesting or out-licensing others. In the third quarter we signed a non-binding term sheet, and are now in contract negotiations for disposition of the C. difficile program, and in October completed the divestment of the PRO 140 program, for which we received $3.5 million cash, together with rights to receive an additional $1.5 million upon commencement of a U.S. or ex-U.S. equivalent phase 3 clinical trial of PRO 140, an additional $5.0 million upon U.S. or E.U. marketing approval of the drug, and a 5% royalty on net sales of approved product(s). Progenics also in the third quarter completed a companywide restructuring, including a workforce reduction and termination of several early stage research projects. Our clinical development and manufacturing capabilities were unaffected by this restructuring.

Our sources of revenues for the three and nine months ended September 30, 2012 and 2011 have been payments under our collaboration agreements, including Relistor royalties, and funds from NIH research grants for expenses incurred in respect of programs we expect to divest or out-license. To date, our product sales have consisted solely of limited revenues from the sale of research reagents and we expect that those sales will not significantly increase over current levels in the near future.

A majority of our expenditures to date have been for research and development activities. During the nine months ended September 30, 2012, expenses for Oncology, primarily related to PSMA ADC, were $23.5 million compared to $15.3 million in 2011. Expenses for Relistor and Other research programs were $1.4 million and $2.6 million, respectively, during the nine months ended September 30, 2012 compared to $22.2 million and $8.2 million, respectively, for the same period in 2011. We expect to incur significant development expenses for our PSMA ADC product candidate as clinical trials progress, while expenses, including reimbursement revenue, related to Relistor depend on the amount of research and development work we perform upon request by Salix or Ono.

At September 30, 2012, we held $41.1 million in cash and cash equivalents, a decrease of $6.7 million from second quarter-end, and a $29.0 million decrease from year-end 2011. We expect that this amount will be sufficient to fund operations as currently anticipated beyond one year. We expect to incur operating losses during the near term. At September 30, 2012, cash, cash equivalents and auction rate securities decreased $29.1 million to $44.3 million from $73.4 million at December 31, 2011.

If we do not realize sufficient royalty or other revenue from Relistor, or are unable to enter into favorable collaboration, license, asset sale, capital raising or other financing transactions, we will have to reduce, delay or eliminate spending on certain programs, and/or reduce headcount and other overhead expenses.

16

Relistor. Relistor has been approved by regulatory authorities in the U.S., countries in the E.U., Canada and Australia since 2008 for treatment of OIC in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient.

Salix is responsible for further developing and commercializing Relistor, including completing clinical development necessary to support regulatory marketing approvals for potential new indications (such as chronic pain) and formulations of the drug, such as oral methylnaltrexone. Under our Agreement with Salix, we are eligible to receive (i) a development milestone of up to $40.0 million upon U.S. marketing approval for subcutaneous Relistor in non-cancer pain patients (the proposed indication addressed in the CRL mentioned above), (ii) a development milestone of up to $50.0 million upon U.S. marketing approval of an oral formulation of Relistor, (iii) up to $200.0 million of commercialization milestone payments upon achievement of specified U.S. sales targets, (iv) royalties ranging from 15 to 19 percent of net sales by Salix and its affiliates, and (v) 60% of any upfront, milestone, reimbursement or other revenue (net of costs of goods sold, as defined, and territory-specific research and development expense reimbursement) Salix receives from sublicensees outside the U.S. (for which we have received $0.2 million to date). In the event that either marketing approval is subject to a Black Box Warning or Risk Evaluation and Mitigation Strategy (REMS), payment of a substantial portion of the milestone amount would be deferred, and subject, to achievement of the first commercialization milestone (payable upon annual U.S. sales first exceeding $100.0 million).

Salix, Progenics, and Progenics' former collaborator Wyeth have transitioned U.S., European and other marketing authorizations and are transitioning additional commercialization outside the U.S. and Japan. Salix has secured distribution and marketing partners for Relistor in the European territory and has licensed Link Medical Products Pty Limited for distribution in Australia, New Zealand, South Africa and certain other markets in Asia. Salix is continuing efforts to secure additional distribution partners and/or sublicensees in Europe and Latin America.

Royalty and milestone payments from Relistor depend on success in development and commercialization, which is dependent on many factors, such as the actions of Salix and Ono, decisions by the FDA and other regulatory bodies, such as the recent CRL mentioned above, the outcome of clinical and other testing of Relistor, and, to the extent requested by our collaboration partners, our own efforts.

Oncology. In September, we opened enrollment in a phase 2 study in prostate cancer patients of our PSMA ADC compound. The trial is an open-label, multicenter study to assess the anti-tumor activity (measured by prostate specific antigen; circulating tumor cells; bone, visceral and nodal metastases; and pain), tolerability and safety of PSMA ADC in up to 75 subjects with metastatic castration-resistant prostate cancer. In June, we presented a summary of current interim results from our phase 1 clinical trial of PSMA ADC at the Plenary Session of the General Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago.

Results of Operations (amounts in thousands unless otherwise noted)
 
Three Months Ended
September 30,
Nine Months Ended
September 30,
2012
2011
Percent
Change
2012
2011
Percent
Change
Revenues
 
$
1,117
   
$
5,804
   
(81%)
 
$
5,163
   
$
82,599
   
(94%)
Expenses
   
(12,432
)
   
(17,251
)
 
(28%)
   
(40,313
)
   
(61,521
)
 
(34%)
Operating (loss) income
   
(11,315
)
   
(11,447
)
 
(1%)
   
(35,150
)
   
21,078
   
(267%)
Other income
   
14
     
15
   
(7%)
   
43
     
49
   
(12%)
Net (loss) income
 
$
(11,301
)
 
$
(11,432
)
 
(1%)
 
$
(35,107
)
 
$
21,127
   
(266%)
 
Revenues:

Our sources of revenue during the three and nine months ended September 30, 2012 and 2011 included our License Agreement with Salix, Transition Agreement with Wyeth, our License Agreement with Ono, our research grants from the NIH and, to a small extent, our sale of research reagents.
 
 
 
Three Months Ended
September 30,
 
 
Nine Months Ended
September 30,
 
Sources of Revenue
 
2012
   
2011
 
Percent
Change
 
2012
   
2011
 
Percent
Change
 
 
   
 
 
   
 
Royalty income
 
$
728
   
$
1,240
   
(41%)
 
$
4,181
   
$
1,767
   
137%
Collaboration revenue
   
136
     
2,855
   
(95%)
   
521
     
76,398
   
(99%)
Research grants
   
243
     
1,681
   
(86%)
   
417
     
4,346
   
(90%)
Other revenues
   
10
     
28
   
(64%)
   
44
     
88
   
(50%)
Total
 
$
1,117
   
$
5,804
   
(81%)
 
$
5,163
   
$
82,599
   
(94%)

17


Royalty income. During the three and nine months ended September 30, 2012 and during the three and nine months ended September 30, 2011, we recognized $728, $4,181, $1,240 and $1,767, respectively, of royalty income based on net sales of Relistor reported by Salix or its sublicensees. No royalties were payable to us during the first quarter of 2011.

 
 
Relistor Net Sales Reported by Collaborators
 
 
Three Months Ended September 30,
   
Nine Months Ended September 30,
 
 
2012
   
2011
   
2012
   
2011
U.S.
 
$
3,800
   
$
8,200
   
$
25,100
   
$
13,500
Ex-U.S.
   
1,100
     
1,500
     
2,900
     
4,700
Global
 
$
4,900
   
$
9,700
   
$
28,000
   
$
18,200

Collaboration revenue:

Salix Collaboration. During the three and nine months ended September 30, 2012, we recognized $130 and $505, respectively, of revenue from Salix, which includes $51 and $153, respectively, from the $60,000 upfront cash payment under the License Agreement and $79 and $352, respectively, as reimbursement of our expenses, in accordance with the License Agreement. As of September 30, 2012, $204 and $9 are recorded in deferred revenue – current and long-term, respectively. During the three and nine months ended September 30, 2011, we recognized $2,854 and $74,738, respectively, of upfront and reimbursement revenue from Salix and we recognized $0 and $1,630, respectively, of revenue from Wyeth, our collaborator before Salix, as reimbursement of our expenses under the 2009 Transition Agreement. We received no such reimbursement in 2012.

Ono Collaboration. During the three months ended September 30, 2012 and 2011, we recognized $6 and $1, respectively and during the nine months ended September 30, 2012 and 2011, we recognized $16 and $30, respectively, of reimbursement revenue for activities requested by Ono under the 2008 Ono Agreement.

Research grants. During the three months ended September 30, 2012 and 2011, we recognized $243 and $1,681, respectively, and during the nine months ended September 30, 2012 and 2011, we recognized $417 and $4,346, respectively, as revenue from federal government grants by the NIH to partially offset costs related to our research and development programs. The decrease in grant revenue resulted from lower reimbursable expenses in 2012 than in 2011. We expect NIH reimbursable expenses to continue to decline.

Other revenues, primarily from orders for research reagents, decreased to $10 for the three months ended September 30, 2012, from $28 for the same period in 2011 and decreased to $44 for the nine months ended September 30, 2012, from $88 for the same period in 2011.

Expenses:

Research and Development Expenses include scientific labor, clinical trial costs, supplies, product manufacturing costs, consulting, license fees, royalty payments and other operating expenses. Research and development expenses decreased to $8,134 for the three months ended September 30, 2012 from $12,667 for the same period of 2011 and decreased to $27,497 for the nine months ended September 30, 2012 from $45,727 for the same period of 2011, as follows:

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Salaries and benefits
 
$
3,992
   
$
5,216
     
(23%)
 
 
$
13,287
   
$
14,868
     
(11%)

Three Months: Salaries and benefits decreased from the 2011 period due to a decline in average headcount to 68 from 102 in the research and development departments and lower bonus accrual in the 2012 period, partially offset by an increase in accrued severance expense related to the headcount reductions.

Nine Months: Salaries and benefits decreased due to a decline in average headcount to 74 from 111 in the research and development departments and lower bonus accrual in the 2012 period, partially offset by an increase in expenses of $1,804 incurred in the first quarter of 2012 in connection with a former senior executive retirement and accrued severance expense, as described above.
18



 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Share-based compensation
 
$
458
   
$
1,243
     
(63%)
 
 
$
4,036
   
$
3,423
     
18%

Three Months: Share-based compensation decreased from the 2011 period primarily due to lower stock option plan, restricted stock and employee stock purchase plan expenses as a result of the 2011 termination of those plans.

Nine Months: Share-based compensation increased primarily due to the acceleration of options and restricted stock expenses of $1,638 resulting from a former senior executive retirement, partially offset by lower restricted stock expenses and lower employee stock purchase plan expenses resulting from the 2011 termination of those plans.

For the nine months ended September 30, 2011, share-based compensation included restricted stock and option plan expenses from (i) accelerated vesting of outstanding awards to non-management employees in connection with a change in program eligibility and termination of the Company's employee stock purchase plans (the latter of which resulted in a decline in share-based compensation), and (ii) a shift in headcount from general and administrative departments to research and development.

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Clinical trial costs
 
$
882
   
$
413
     
114%
 
 
$
1,961
   
$
9,685
     
(80%)

Three Months: Clinical trial costs increased from the 2011 period primarily due to higher expenses in Oncology ($622), primarily related to PSMA ADC, and Other ($15), partially offset by lower expenses for Relistor ($168), resulting from lower clinical trial activities expense related to the oral methylnaltrexone phase 3 study assumed by Salix in 2011.

Nine Months: Clinical trial costs decreased primarily due to Relistor ($9,090), resulting from lower clinical trial activities expense related to the oral methylnaltrexone study, and Other ($43), partially offset by increased expenses in Oncology ($1,409), primarily related to PSMA ADC.

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Laboratory and manufacturing supplies
 
$
95
   
$
2,572
     
(96%)
 
 
$
472
   
$
3,948
     
(88%)

Three Months: Laboratory and manufacturing supplies decreased from the 2011 period due to lower expenses in (i) Relistor ($2,120), (ii) Oncology ($18), resulting from a decline in manufacturing supplies for PSMA ADC, and (iii) Other ($339).

Nine Months: Laboratory and manufacturing supplies decreased due to lower expenses in (i) Relistor ($2,197), (ii) Oncology ($341), resulting from a decline in manufacturing supplies for PSMA ADC, and (iii) Other ($938).

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Contract manufacturing and subcontractors
 
$
821
   
$
1,009
     
(19%)
 
 
$
2,445
   
$
5,872
     
(58%)

Three Months: Contract manufacturing and subcontractors decreased from the 2011 period due to lower expenses for Relistor ($8), resulting from a decrease in purchases of subcutaneous Relistor related products, and Other ($373), partially offset by an increase in Oncology ($193).
19


Nine Months: Contract manufacturing and subcontractors decreased due to lower expenses for Relistor ($2,213), resulting from a decrease in purchases of subcutaneous Relistor related products, and Other ($1,469), partially offset by an increase in Oncology ($255).

Expenses in this category relate to the conduct of clinical trials, including manufacture by third parties of drug materials, testing, analysis, formulation and toxicology services, and vary as the timing and level of such services are required.

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Consultants
 
$
45
   
$
164
     
(73%)
 
 
$
268
   
$
1,143
     
(77%)

Three Months: Consultants expense decreased from the 2011 period due to lower expenses for Relistor ($57), Oncology ($43) and Other programs ($19).

Nine Months: Consultants expense decreased due to lower expenses for Relistor ($811), primarily related to the sNDA submission for subcutaneous Relistor in non-cancer pain patients, Oncology ($14) and Other programs ($50).

Expenses in this category relate to monitoring ongoing clinical trials and reviewing data from completed trials including the preparation of filings and vary as the timing and level of such services are required.

 
 
Three Months Ended September 30,
   
   
Six Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
License fees
 
$
510
   
$
114
     
347%
 
 
$
660
   
$
566
     
17%

Three Months: License fees increased due to higher expenses for Oncology ($401), partially offset by lower expenses for Relistor ($4) and Other ($1).

Nine Months: License fees increased due to higher expenses for Oncology ($402), partially offset by lower expenses for Relistor ($156) and Other ($152).

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Royalty expense
 
$
73
   
$
147
     
(50%)
 
 
$
420
   
$
274
     
53%

Three Months: We recognized $73 and $147, respectively, of royalty expenses during the three months ended September 30, 2012 and 2011, and the decrease in expenses is due to lower net sales of Relistor in the 2012 period.

Nine Months: We recognized $420 and $274, respectively, of royalty expenses during the nine months ended September 30, 2012 and 2011, and the increase in expenses is due to higher net sales of Relistor in 2012.

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Other operating expenses
 
$
1,258
   
$
1,789
     
(30%)
 
 
$
3,948
   
$
5,948
     
(34%)

Three Months: Other operating expenses decreased from the 2011 period primarily due to decreases in rent ($377), facilities ($52), insurance ($35), travel ($20) and other operating expenses ($47).

Nine Months: Other operating expenses decreased primarily due to decreases in rent ($1,568), travel ($112), insurance ($37) and other operating expenses ($409), partially offset by increases in expenses for facilities ($126).
20


General and Administrative Expenses decreased to $4,007 for the three months ended September 30, 2012 from $4,064 for the same period of 2011 and decreased to $11,753 for the nine months ended September 30, 2012, from $14,213 for the same period of 2011, as follows:

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Salaries and benefits
 
$
2,151
   
$
1,918
     
12%
 
 
$
5,606
   
$
5,748
     
(2%)

Three Months: Salaries and benefits increased from the 2011 period due to an increase in accrued severance expense related to the headcount reductions, partially offset by a decrease in salary expenses due to a decline in average headcount to 24 from 30 and lower bonus accrual in the 2012 period, in the general and administrative departments.

Nine Months: Salaries and benefits decreased due to a decline in average headcount to 26 from 33, in the general and administrative departments and lower bonus accrual in the 2012 period, partially offset by an increase in accrued severance expense, as described above.

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Share-based compensation
 
$
496
   
$
179
     
177%
 
 
$
1,714
   
$
1,272
     
35%

Three Months: Share-based compensation increased from the 2011 period due to higher stock option and restricted stock expenses in connection with the third quarter 2012 restructuring, partially offset by lower employee stock purchase plan expenses, as a result of the 2011 termination of those plans.

Nine Months: Share-based compensation increased due to higher stock option expenses, partially offset by lower restricted stock expenses and lower employee stock purchase plan expenses, resulting from the 2011 termination of those plans.

For the nine months ended September 30, 2011, share-based compensation reflected accelerated vesting in connection with termination of our employee stock purchase plans, as described under research and development expenses, above.

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Consulting and professional fees
 
$
475
   
$
816
     
(42%)
 
 
$
1,579
   
$
3,636
     
(57%)

Three Months: Consulting and professional fees decreased from the 2011 period due to lower consulting ($181), audit ($94) and legal fees ($68), partially offset by higher other fees ($2).

Nine Months: Consulting and professional fees decreased due to lower consulting ($1,204), patent ($472), audit ($229) and other fees ($152).

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Other operating expenses
 
$
885
   
$
1,151
     
(23%)
 
 
$
2,854
   
$
3,557
     
(20%)

Three Months: Other operating expenses decreased from the 2011 period due to lower expenses for rent ($125), investor relations ($30), taxes ($30) and other operating expenses ($135), partially offset by an increase in recruiting ($54).

Nine Months: Other operating expenses decreased due to lower expenses for rent ($518), investor relations ($64) and other
operating expenses ($243), partially offset by an increase in recruiting ($122).

21

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Depreciation and amortization
 
$
291
   
$
520
     
(44%)
 
 
$
1,063
   
$
1,581
     
(33%)

Three Months: Depreciation and amortization expense decreased to $291 from $520 for the 2011 period, primarily due to lower machinery and equipment fixed assets balances.

Nine Months: Depreciation and amortization expense decreased to $1,063 from $1,581 for the 2011 period, primarily due to lower machinery and equipment fixed assets balances.

Other income:

 
 
Three Months Ended September 30,
   
   
Nine Months Ended September 30,
   
 
 
2012
   
2011
   
Percent
Change
   
2012
   
2011
   
Percent
Change
 
 
   
   
   
   
   
Interest income
 
$
14
   
$
15
     
(7%)
 
 
$
43
   
$
49
     
(12%)

Three Months: Interest income decreased to $14 from $15 for the 2011 period, due to lower average balance of cash equivalents in 2012 than in 2011.

Nine Months: Interest income decreased to $43 from $49 for the 2011 period, due to lower average balance of cash equivalents in 2012 than in 2011.

Income Taxes:

For the three and nine months ended September 30, 2012 and for the three months ended September 30, 2011, our pre-tax losses were $11,301, $35,107 and $11,432, respectively. As a result of the $60,000 Salix upfront cash payment received in 2011, our pre-tax income was $21,127 for the nine months ended September 30, 2011, and we had taxable income in 2011, which has been offset fully with net operating loss carry-forwards.

Net (Loss) Income:

Our net loss was $11,301 and $35,107 for the three and nine months ended September 30, 2012, respectively, compared to net loss of $11,432 for the three months ended September 30, 2011 and income of $21,127 for the nine months ended September 30, 2011.

Liquidity and Capital Resources

We currently use cash on hand and royalty payments from Relistor to fund our ongoing operations. We expect to continue to use cash on hand and future Relistor royalties and other revenues, including any future development and/or commercialization milestones, as well as payments we may receive for licenses or other transactions involving other proprietary assets and programs, to fund our operations in the future. In the past, and to a limited extent currently, we have also funded operations through payments received from private placements of equity securities, public offerings of common stock, other collaborations, grants and contracts, royalties, interest on investments, and proceeds from the exercise of outstanding options and warrants.

Under the Salix License Agreement, we received in 2011 a $60,000 upfront cash payment and $225 in respect of Salix ex-U.S. sublicensee revenue and are eligible to receive development and commercialization milestone payments plus royalties on net sales and 60% of any upfront, milestone, reimbursement or other revenue (net of costs of goods sold, as defined, and territory-specific research and development expense reimbursement) Salix receives from ex-U.S. sublicensees.

Our expenses and reimbursement revenue related to Relistor have declined substantially since Salix assumed direct responsibility for expenses under third-party contracts we have assigned to it. Under the Salix License Agreement, we are reimbursed for Salix approved full-time equivalents (FTE) and third-party development expenses incurred and paid by us after February 3, 2011.
22

 
At September 30, 2012, we held $41,096 in cash and cash equivalents, a decrease of $6,724 from $47,820 at June 30, 2012, and a decrease of $29,009 from $70,105 at December 31, 2011. We expect that this amount will be sufficient to fund operations as currently anticipated beyond one year. In addition, at September 30, 2012, our investment in auction rate securities classified as long-term assets on the Consolidated Balance Sheets amounted to $3,240.

If we do not realize sufficient royalty or other revenue from Relistor, or are unable to enter into favorable collaboration, license, asset sale, capital raising or other financing transactions, we will have to reduce, delay or eliminate spending on certain programs, and/or reduce headcount and other overhead expenses.

Our cash flow from operating activities was negative for the nine months ended September 30, 2012, due primarily to the excess of expenditures on our research and development programs and general and administrative costs over cash received from collaborators and government grants to fund such programs, as described below. Our cash flow from operating activities was positive for the nine months ended September 30, 2011, due to the receipt in 2011 of a $60,000 Salix upfront payment from Salix, partially offset by expenditures on our research and development programs and general and administrative costs.

Sources of Cash

Operating Activities. During the nine months ended September 30, 2012 we received $5,078 under our collaborations, consisting of (i) $323 in reimbursement payments under the Salix License Agreement, (ii) $4,732 in royalties from Salix and (iii) $23 under the License Agreement with Ono. During the nine months ended September 30, 2011, we received $78,010 under our collaborations, consisting of (i) $60,000 Salix upfront cash payment, (ii) $13,912 in reimbursement payments under the Salix License Agreement, (iii) $225 in respect of Salix ex-U.S. sublicensee revenue, (iv) $527 in royalties from Salix, (v) $3,317 under the Transition Agreement with Wyeth, and (vi) $29 under the License Agreement with Ono.

We have partially funded research programs through awards from the NIH. For the nine months ended September 30, 2012 and 2011, we received $431 and $4,275, respectively, of revenue from all of our NIH awards. We expect a further decline in NIH reimbursable expenses.

Changes in Accounts receivable and Accounts payable for the nine months ended September 30, 2012 and 2011 resulted from the timing of receipts from Salix, the NIH, Wyeth and Ono, and payments made to trade vendors in the normal course of business.

Other than amounts to be received from Salix and Ono, we have no committed external sources of capital. Other than revenues from Relistor, we expect no significant product revenues for a number of years, as it will take at least that much time, if ever, to bring our product candidates to the commercial marketing stage.

Investing Activities. Of $41,096 in cash and cash equivalents primarily invested in money market funds of which, at September 30, 2012, $33,326 is guaranteed by the U.S. Treasury or Federal Deposit Insurance Corporation's guarantee program. Our auction rate securities of $3,240 include $2,300 of securities collateralized by student loan obligations subsidized by the U.S. government, $100 of which was redeemed at par during the first quarter of 2012. These investments, while rated investment grade by the Standard & Poor's and Moody's rating agencies and predominantly having scheduled maturities greater than ten years, are heavily concentrated in the U.S. financial sector. During the nine months ended September 30, 2012, proceeds from sales of fixed assets were $368.

Financing Activities. During the nine months ended September 30, 2012 and 2011, we received cash of $196 and $3,234, respectively, from the exercise of stock options and, in 2011, from the sale of our common stock under our employee stock purchase plan. The amount of cash we receive from these sources fluctuates commensurate with headcount levels and changes in the price of our common stock on the grant date for options exercised, and on the sale date for shares sold under now-terminated employee stock purchase plans.

Unless we obtain regulatory approval from the FDA for additional product candidates and/or enter into agreements with corporate collaborators with respect to our additional technologies, we will be required to fund our operations in the future through sales of common stock or other securities, royalty or other financing agreements and/or grants and government contracts. Adequate additional funding may not be available to us on acceptable terms or at all. Our inability to raise additional capital on terms reasonably acceptable to us may seriously jeopardize the future success of our business.
23

 
Uses of Cash

Operating Activities. The majority of our cash has been used to advance our research and development programs, including conducting pre-clinical studies and clinical trials, pursuing regulatory approvals for product candidates, filing and prosecuting patent applications and defending patent claims. Our expenses for research and development for the nine months ended September 30, 2012 and 2011 were $27,497 and $45,727, respectively. Included in the 2012 period is $2,066 of cash disbursements incurred in connection with a former senior executive first quarter retirement. For various reasons, including the early stage of certain of our programs, the timing and results of our clinical trials, our dependence in certain instances on third parties, many of which are outside of our control, we cannot estimate the total remaining costs to be incurred and timing to complete all our research and development programs.

Investing Activities. During the nine months ended September 30, 2012 and 2011, we have spent $759 and $142, respectively, on capital expenditures.

Contractual Obligations

Our funding requirements, both for the next 12 months and beyond, will include required payments under operating leases and fixed and contingent payments under our licensing, collaboration and other agreements. The following table summarizes our contractual obligations as of September 30, 2012 for future payments under these agreements:

 
 
   
Payments due by September 30,
 
 
Total
   
2013
     
2014-2015
     
2016-2017
   
Thereafter
 
 
(in millions)
Operating leases
 
$
21.2
   
$
2.4
   
$
4.9
   
$
5.1
   
$
8.8
License, collaboration and other agreements:
                                     
Fixed payments
   
1.7
     
0.3
     
0.5
     
0.6
     
0.3
Contingent payments (1)
   
77.8
     
0.5
     
2.3
     
3.0
     
72.0
Total
 
$
100.7
   
$
3.2
   
$
7.7
   
$
8.7
   
$
81.1
  _______________
 
(1)
Based on assumed achievement of milestones covered under each agreement, the timing and payment of which is highly uncertain.

We periodically assess the scientific progress and merits of each of our programs to determine if continued research and development is commercially and economically viable. Certain of our programs have been terminated due to the lack of scientific progress and prospects for ultimate commercialization. Because of the uncertainties associated with research and development in these programs, the duration and completion costs of our research and development projects are difficult to estimate and are subject to considerable variation. Our inability to complete research and development projects in a timely manner or failure to enter into collaborative agreements could significantly increase capital requirements and adversely affect our liquidity.

Our cash requirements may vary materially from those now planned because of results of research and development and product testing, changes in existing relationships or new relationships with licensees, licensors or other collaborators, changes in the focus and direction of our research and development programs, competitive and technological advances, the cost of filing, prosecuting, defending and enforcing patent claims, the regulatory approval process, manufacturing and marketing and other costs associated with the commercialization of products following receipt of regulatory approvals and other factors.

The above discussion contains forward-looking statements based on our current operating plan and the assumptions on which it relies. There could be deviations from that plan that would consume our assets earlier than planned.

Off-Balance Sheet Arrangements and Guarantees

We have no obligations under off-balance sheet arrangements and do not guarantee the obligations of any other unconsolidated entity.

24

Critical Accounting Policies

We prepare our financial statements in conformity with accounting principles generally accepted in the United States of America. Our significant accounting policies are disclosed in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2011. The selection and application of these accounting principles and methods requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as certain financial statement disclosures. On an ongoing basis, we evaluate our estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results of our evaluation form the basis for making judgments about the carrying values of assets and liabilities that are not otherwise readily apparent. While we believe that the estimates and assumptions we use in preparing the financial statements are appropriate, these estimates and assumptions are subject to a number of factors and uncertainties regarding their ultimate outcome and, therefore, actual results could differ from these estimates.

There have been no other changes to our critical accounting policies and estimates as of and for the nine months ended September 30, 2012, which are disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations included in our 2011 Annual Report on Form 10-K.

Item 3.  Quantitative and Qualitative Disclosures about Market Risk (amounts in thousands unless otherwise noted)
 
Our primary investment objective is to preserve principal. Our money market funds and auction rate securities have interest rates that were variable and totaled $39,451 at September 30, 2012. As a result, we do not believe that these investment balances have a material exposure to interest-rate risk.

At September 30, 2012, we continue to hold approximately $3,240 (8.2% of assets measured at fair value) of auction rate securities, in respect of which we have received all scheduled interest payments. The principal amount of these remaining auction rate securities will not be accessible until the issuer calls or restructures the underlying security, the underlying security matures and is paid or a buyer outside the auction process emerges.

We continue to monitor the market for auction rate securities and consider the impact, if any, of market conditions on the fair market value of our investments. We believe that the failed auctions experienced to date are not a result of the deterioration of the underlying credit quality of these securities, although valuation of them is subject to uncertainties that are difficult to predict, such as changes to credit ratings of the securities and/or the underlying assets supporting them, default rates applicable to the underlying assets, underlying collateral value, discount rates, counterparty risk, ongoing strength and quality of market credit and liquidity, and general economic and market conditions. We do not believe the carrying values of these auction rate securities are other than temporarily impaired and therefore expect the positions will eventually be liquidated without significant loss.

The valuation of the auction rate securities we hold is based on an internal analysis of timing of expected future successful auctions, collateralization of underlying assets of the security and credit quality of the security. We re-evaluated the valuation of these securities as of September 30, 2012 and the temporary impairment amount decreased $8 from $268 at December 31, 2011 to $260. A 100 basis point increase to our internal analysis would result in a $35 increase in the temporary impairment of these securities as of the nine months ended September 30, 2012.

Item 4.  Controls and Procedures

We maintain disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the U.S. Securities Exchange Act of 1934, that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (CEO) and Treasurer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have a Disclosure Committee consisting of certain members of our senior management which monitors and implements our policy of disclosing material information concerning the Company in accordance with applicable law.

The Disclosure Committee, under the supervision and with the participation of our senior management, including our CEO and Treasurer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon their evaluation and subject to the foregoing, the CEO and Treasurer concluded that our disclosure controls and procedures, as designed and implemented, were effective at the reasonable assurance level.

There have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
25



PART II — OTHER INFORMATION

Item 1A. Risk Factors

Our business and operations entail a variety of serious risks and uncertainties, including those described in Item 1A of our Form 10-K for the year ended December 31, 2011 and our other public reports.
26


Item 6. Exhibits

(a)            Exhibits

Exhibit Number
Description
 
 
12.1
Statement re computation of ratio of earnings (loss) to combined fixed charges and preferred stock dividends.
 
 
31.1
Certification of Mark R. Baker, Chief Executive Officer of the Registrant, pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
 
 
31.2
Certification of Angelo W. Lovallo, Jr., Senior Executive Director, Financial Reporting & Treasurer of the Registrant, pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
 
 
32
Certification of the Chief Executive Officer and Treasurer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
101
Interactive Data File
 
 
101.INS
XBRL Instance Document
 
 
101.SCH
XBRL Taxonomy Extension Schema
 
 
101.CAL
XBRL Taxonomy Extension Calculation Linkbase
 
 
101.LAB
XBRL Taxonomy Extension Label Linkbase
 
 
101.PRE
XBRL Taxonomy Extension Presentation Linkbase
 
 
101.DEF
XBRL Taxonomy Extension Definition Document
 
 
27



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
PROGENICS PHARMACEUTICALS, INC.
Date: November 8, 2012
By:
/s/ Angelo W. Lovallo, Jr.
 
 
Angelo W. Lovallo, Jr.
Senior Executive Director
Financial Reporting & Treasurer
(Principal Financial and Accounting Officer)

28